Organon & Co. (NYSE:OGN) Issues Earnings Results, Misses Estimates By $0.05 EPS

Posted by George Bondi on Aug 1st, 2026

Organon & Co. (NYSE:OGN – Get Free Report) issued its quarterly earnings results on Friday. The company reported $0.85 EPS for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.05), FiscalAI reports. The firm had revenue of $1.56 billion for the quarter, compared to analyst estimates of $1.57 billion. Organon & Co. had a return on equity of 99.95% and a net margin of 3.99%.

Organon & Co. Stock Performance

Shares of OGN opened at $13.55 on Friday. Organon & Co. has a 1 year low of $5.69 and a 1 year high of $13.60. The stock has a 50-day simple moving average of $13.47 and a 200-day simple moving average of $10.40. The company has a debt-to-equity ratio of 9.47, a quick ratio of 1.42 and a current ratio of 1.97. The stock has a market capitalization of $3.56 billion, a PE ratio of 14.58, a PEG ratio of 1.25 and a beta of 1.54.

Organon & Co. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a $0.02 dividend. The ex-dividend date is Friday, August 14th. This represents a $0.08 dividend on an annualized basis and a yield of 0.6%. Organon & Co.’s dividend payout ratio (DPR) is 8.60%.

More Organon & Co. News

Here are the key news stories impacting Organon & Co. this week:

Positive Sentiment: Organon declared a quarterly dividend of $0.02 per share, payable September 10 to shareholders of record on August 14. The annualized payout is approximately $0.08 per share, representing a yield of about 0.6%. Organon Announces Quarterly Dividend
Neutral Sentiment: The company reported second-quarter results while its proposed merger with Sun Pharma remains pending, keeping the transaction an important factor for investors evaluating Organon’s future ownership and strategy. Organon Reports Q2 Results Amid Pending Sun Pharma Merger
Negative Sentiment: Second-quarter adjusted earnings were $0.85 per share, below the $0.87 consensus estimate and down from $1.00 a year earlier. Revenue of $1.56 billion also narrowly missed the $1.57 billion analyst forecast, signaling softer-than-expected quarterly performance. Organon Lags Q2 Earnings Estimates
Negative Sentiment: The earnings miss and year-over-year EPS decline may weigh on the stock because they raise questions about near-term growth and profitability, despite the company’s dividend support. Organon Q2 Earnings Snapshot

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Zacks Research upgraded Organon & Co. from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 14th. Piper Sandler upgraded shares of Organon & Co. from an “underweight” rating to a “neutral” rating and increased their price target for the stock from $5.00 to $14.00 in a report on Tuesday, April 28th. Weiss Ratings raised shares of Organon & Co. from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, July 13th. Finally, BNP Paribas Exane restated a “neutral” rating and set a $14.00 price objective (up from $12.00) on shares of Organon & Co. in a research note on Wednesday, April 29th. Five analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Reduce” and a consensus target price of $11.40.

Get Our Latest Research Report on OGN

Insider Transactions at Organon & Co.

In other Organon & Co. news, SVP Lynette Holzbaur bought 26,448 shares of the firm’s stock in a transaction that occurred on Wednesday, May 6th. The stock was purchased at an average price of $13.35 per share, for a total transaction of $353,080.80. Following the completion of the purchase, the senior vice president directly owned 52,851 shares in the company, valued at $705,560.85. This trade represents a 100.17% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.62% of the stock is owned by company insiders.

Institutional Investors Weigh In On Organon & Co.

Several large investors have recently modified their holdings of the company. Integrated Wealth Concepts LLC increased its position in Organon & Co. by 2.8% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 58,648 shares of the company’s stock valued at $626,000 after acquiring an additional 1,594 shares during the period. Rafferty Asset Management LLC increased its stake in shares of Organon & Co. by 8.5% during the second quarter. Rafferty Asset Management LLC now owns 23,578 shares of the company’s stock worth $228,000 after acquiring an additional 1,847 shares during the period. Bank of Nova Scotia increased its position in Organon & Co. by 4.6% during the 3rd quarter. Bank of Nova Scotia now owns 44,512 shares of the company’s stock worth $475,000 after purchasing an additional 1,947 shares during the period. Vise Technologies Inc. raised its stake in shares of Organon & Co. by 10.2% during the 3rd quarter. Vise Technologies Inc. now owns 25,377 shares of the company’s stock worth $271,000 after buying an additional 2,358 shares in the last quarter. Finally, Parallel Advisors LLC raised its stake in shares of Organon & Co. by 23.2% during the 3rd quarter. Parallel Advisors LLC now owns 16,014 shares of the company’s stock worth $171,000 after buying an additional 3,020 shares in the last quarter. 77.43% of the stock is owned by institutional investors and hedge funds.

About Organon & Co.

(Get Free Report)

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.